人甲状旁腺激素1-34治疗儿童家族性甲状旁腺功能减退症中的骨骼健康与线性生长
本研究为二次分析,汇总了平均基线年龄13.7±5.5岁的甲状旁腺功能减退症患者的线性生长和腰椎双能X线吸收测定数据,比较18例APS-1与9例CaR患者。PTH治疗期间,APS-1组平均HAZ在所有年龄均低于0,而CaR组HAZ升高(年龄与分组交互作用P<.0001)。两组平均LS-BMD-Z均正常(0±1),LS-TBS-Z在CaR组随时间上升而APS-1组维持约0(时间与分组交互作用P=.02)。
要点
- PTH治疗期间APS-1组平均HAZ在所有年龄均低于0,CaR组HAZ升高(交互作用P<.0001)。
- 两组平均LS-BMD-Z均正常(0±1),LS-TBS-Z在CaR组随时间上升而APS-1组维持约0(P=.02)。
- APS-1病情较重(≥7种表现)者LS-BMD-Z和LS-TBS-Z低于较轻APS-1或CaR组。
核心结论
- 本研究凸显APS-1与CaR在生长和骨密度模式上的差异,并强调需要仔细监测和个体化治疗策略以优化生长和骨骼健康。
研究设计与样本
- 二次分析,汇总了甲状旁腺功能减退症研究中平均基线年龄13.7±5.5岁的线性生长和腰椎双能X线吸收测定数据。
- 比较18例APS-1与9例CaR两种诊断病因,使用纵向混合效应模型检验年龄和PTH治疗时长对HAZ、LS-BMD-Z和LS-TBS-Z的影响。
主要发现
- PTH治疗期间,APS-1组平均HAZ在所有年龄均低于0,而CaR组HAZ升高(年龄与分组交互作用P<.0001)。
- 两组平均LS-BMD-Z均正常(BMD-Z:0±1)。
- 两组平均LS-TBS-Z接近或高于0且组间不同;CaR组随PTH治疗时间呈上升轨迹,而APS-1组维持LS-TBS-Z约0(时间与分组交互作用P=.02)。
- APS-1病情较重(≥7种表现)组LS-BMD-Z和LS-TBS-Z低于较轻APS-1或CaR组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Our study explores the impact of human parathyroid hormone (PTH) 1-34 injections (PTH therapy) on growth, areal bone mineral density (BMD), and bone quality (measured by trabecular bone score, TBS) in hypoparathyroidism due to autoimmune polyendocrine syndrome type 1 (APS-1) or an activating variant of the calcium sensing receptor (CaR). OBJECTIVE: To assess associations of (1) age and PTH therapy duration with age-standardized Z-scores for height (HAZ), BMD (BMD-Z), and TBS (TBS-Z) in CaR or APS-1, and (2) APS-1 disease severity with BMD-Z and TBS-Z. METHODS: This secondary analysis pooled linear growth and lumbar spine (LS) dual-energy x-ray absorptiometry data from studies of hypoparathyroidism with mean baseline age of 13.7 ± 5.5 years. Comparing the 2 diagnostic etiologies (18 APS-1 and 9 CaR), we examined the impact of age and PTH duration on HAZ, LS-BMD-Z, and LS-TBS-Z using longitudinal mixed-effects modeling. RESULTS: During PTH therapy, mean HAZ remained below 0 in the APS-1 group at all ages, whereas HAZ increased in the CaR group (age by group interaction P < .0001). Mean LS-BMD-Z were normal (BMD-Z: 0 ± 1) for both groups. Mean LS-TBS-Z were near or above 0 and differed by group; CaR showed an upward trajectory according to time on PTH whereas the APS-1 group maintained a LS-TBS-Z of approximately 0 (time by group interaction P = .02). The APS-1 group with greater disease severity (≥7 manifestations) had lower LS-BMD-Z and LS-TBS-Z than the less severe APS-1 or CaR groups. CONCLUSION: Our study highlights distinct growth and BMD patterns in APS-1 and CaR and underscores the need for careful monitoring and tailored treatment strategies to optimize growth and bone health.
引用
- Winer KK, Zemel BS, Kelly A, et al. Bone Health and Linear Growth in Children With Familial Hypoparathyroidism Treated With Human Parathyroid Hormone 1-34. J Clin Endocrinol Metab. 2025. PMID: 39883563. doi:10.1210/clinem/dgaf065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。